Skip to content

Dexmedetomidine as an Adjuvant in External Oblique Intercostal Plane Block for Post Thoracotomy Pain

Role of Dexmedetomidine as an Adjuvant in External Oblique Intercostal Plane Block for Post Thoracotomy Pain: A Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06684535
Enrollment
40
Registered
2024-11-12
Start date
2024-11-14
Completion date
2025-07-07
Last updated
2025-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adjuvant, Dexmedetomidine, External Oblique Intercostal Plane Block, Pain, Thoracotomy

Brief summary

This study aims to evaluate the role of dexmedetomidine as an adjuvant in external oblique intercostal plane block for post-thoracotomy pain.

Detailed description

External oblique intercostal plane block (EOIPB) is a novel block that has been described as an important modification of the fascial plane blocks that can consistently involve the upper lateral abdominal walls. Dexmedetomidine is a selective alpha 2- adrenoceptor agonist possessing sedative, anxiolytic, and analgesic properties without the development of respiratory depression.

Interventions

DRUGDexmedetomidine

Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg.

DRUGSaline

Patients will receive 29 ml bupivacaine 0.25% + 1 ml saline.

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years. * Both sexes. * American Society of Anesthesiology (ASA) physical status I-III. * Scheduled for open thoracotomy.

Exclusion criteria

* Patients with neurological or intellectual disability. * Infection at the injection site. * Drug abuse. * Allergic reaction to local anesthetics. * Coagulation abnormalities. * Pregnancy. * Body Mass Index (BMI) ≥35 kg/m2. * Severe cardiovascular problems. * Diabetic neuropathy.

Design outcomes

Primary

MeasureTime frameDescription
Time to the 1st rescue analgesia48 hours postoperativelyTime to the first request for the rescue analgesia (time from end of surgery to first dose of morphine administrated) will be recorded.

Secondary

MeasureTime frameDescription
Intraoperative fentanyl consumptionIntraoperativelyAdditional fentanyl bolus dosages of 1 µg/kg IV will be administered if heart rate or mean arterial blood pressure elevated more than 20% of the baseline.
Total morphine consumption48 hours postoperativelyRescue analgesia of morphine will be given as 3 mg bolus if the numeric rating scale (NRS) \> 3 to be repeated after 30 min if pain persists until the NRS \< 4.
Heart rateEvery 15 min till the end of surgeryHeart rate will be recorded preoperative, before performing of block, and every 15 min till the end of surgery.
Mean arterial pressureEvery 15 min till the end of surgeryMean arterial pressure will be recorded preoperative, before performing of block, and every 15 min till the end of surgery.
Incidence of adverse events48 hours postoperativelyIncidence of adverse events such as pneumothorax, local anesthetic systemic toxicity (LAST), bradycardia, hypotension, nausea, vomiting, respiratory depression, or any other complication will be recorded.
Degree of pain48 hours postoperativelyEach patient will be instructed about postoperative pain assessment with the numeric rating scale (NRS). NRS (0 represents no pain while 10 represents the worst pain imaginable). NRS will be assessed at 0, 4, 8, 12, 18, 24, 36 and 48 h postoperatively.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026